← Back to Search

Pneumococcal Conjugate Vaccine

Candidate-5 for Pneumococcal Diseases

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 7 days after study intervention
Awards & highlights

Study Summary

This trial is to study if Pneumococcal Conjugate Formulations can help build immunity against disease in healthy adults 18-49 years old.

Eligible Conditions
  • Pneumococcal Diseases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 7 days after study intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 7 days after study intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Adverse Events (AE) Within 1 Month After Administration of Study Intervention
Percentage of Participants With Local Reactions Within 7 Days After Administration of Study Intervention
Percentage of Participants With Serious Adverse Events (SAE) Within 1 Month After Administration of Study Intervention
+1 more
Secondary outcome measures
Serotype Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Administration of Study Intervention From Each Candidate and Candidate Control Group

Side effects data

From 2022 Phase 1 trial • 394 Patients • NCT05489328
44%
Headache (HEADACHE)
32%
Fatigue (FATIGUE)
12%
Injection site pain (PAIN)
12%
Myalgia (MUSCLE PAIN)
2%
Pyrexia (FEVER)
2%
Arthralgia (JOINT PAIN)
100%
80%
60%
40%
20%
0%
Study treatment Arm
Candidate-1
Candidate-2
PCV15
Candidate-4
Candidate-3
Candidate - Control
Candidate-6
Candidate-5
13vPnC

Trial Design

9Treatment groups
Experimental Treatment
Active Control
Group I: Candidate-6Experimental Treatment1 Intervention
Participants to receive a single injection of Candidate-6.
Group II: Candidate-5Experimental Treatment1 Intervention
Participants to receive a single injection of Candidate-5.
Group III: Candidate-4Experimental Treatment1 Intervention
Participants to receive a single injection of Candidate-4.
Group IV: Candidate-3Experimental Treatment1 Intervention
Participants to receive a single injection of Candidate-3.
Group V: Candidate-2Experimental Treatment1 Intervention
Participants to receive a single injection of Candidate-2.
Group VI: Candidate-1Experimental Treatment1 Intervention
Participants to receive a single injection of Candidate-1.
Group VII: 15-valent pneumococcal conjugate vaccine (PCV15)Experimental Treatment1 Intervention
Participants to receive a single injection of PCV15.
Group VIII: 13-valent pneumococcal conjugate vaccine (13vPnC)Experimental Treatment1 Intervention
Participants to receive a single injection of 13vPnC.
Group IX: Candidate ControlActive Control1 Intervention
Participants to receive a single injection of Candidate Control.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
13vPnC
2018
Completed Phase 4
~9930
PCV15
2022
Completed Phase 3
~1950

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,570 Previous Clinical Trials
10,915,612 Total Patients Enrolled
26 Trials studying Pneumococcal Diseases
106,945 Patients Enrolled for Pneumococcal Diseases
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,476 Previous Clinical Trials
8,091,827 Total Patients Enrolled
26 Trials studying Pneumococcal Diseases
106,945 Patients Enrolled for Pneumococcal Diseases

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
2022. "Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05489328.
~148 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top